Cargando…

Combining proteomic markers to construct a logistic regression model for polycystic ovary syndrome

INTRODUCTION: Proteomics technology has been used in various fields in recent years for the Q6 exploration of novel markers and the study of disease pathogenesis, and has become one of the most important tools for researchers to explore unknown areas. However, there are fewer studies related to the...

Descripción completa

Detalles Bibliográficos
Autores principales: Tong, Cheng, Wu, Yue, Zhuang, Zhenchao, Wang, Zhejiong, Yu, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579946/
https://www.ncbi.nlm.nih.gov/pubmed/37854181
http://dx.doi.org/10.3389/fendo.2023.1227252
_version_ 1785121842698125312
author Tong, Cheng
Wu, Yue
Zhuang, Zhenchao
Wang, Zhejiong
Yu, Ying
author_facet Tong, Cheng
Wu, Yue
Zhuang, Zhenchao
Wang, Zhejiong
Yu, Ying
author_sort Tong, Cheng
collection PubMed
description INTRODUCTION: Proteomics technology has been used in various fields in recent years for the Q6 exploration of novel markers and the study of disease pathogenesis, and has become one of the most important tools for researchers to explore unknown areas. However, there are fewer studies related to the construction of clinical models using proteomics markers. METHODS: In our previous study we used DIA proteomics to screen for proteins that were significant in 31 PCOS patients compared to women of normal reproductive age. In this study, we used logistic regression among these protein markers to screen out variables with diagnostic value and constructed logistic regression models. RESULTS: We constructed a logistic model using these protein markers, where HIST1H4A (OR=1.037) was an independent risk factor for polycystic ovary syndrome and TREML1 (OR=0.976) were protective factors for the disease. The logistic regression model equation is: Logit (PCOS) =0.036*[HIST1H4A]-0.024*[TREML1]-16.368. The ROC curve analyzing the diagnostic value of the model has an AUC value of 0.977 and a Youden index of0.903, which gives a cutoff value of 0.518 at this point. The model has a sensitivity of 93.5% and a specificity of 96.8%. Calibration curves show fair consistency of the model. DISCUSSION: Our study is the first to use proteomic results with clinical biochemical data to construct a logistic regression model, and the model is consistent. However, our study still needs a more complete sample to confirm our findings.
format Online
Article
Text
id pubmed-10579946
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-105799462023-10-18 Combining proteomic markers to construct a logistic regression model for polycystic ovary syndrome Tong, Cheng Wu, Yue Zhuang, Zhenchao Wang, Zhejiong Yu, Ying Front Endocrinol (Lausanne) Endocrinology INTRODUCTION: Proteomics technology has been used in various fields in recent years for the Q6 exploration of novel markers and the study of disease pathogenesis, and has become one of the most important tools for researchers to explore unknown areas. However, there are fewer studies related to the construction of clinical models using proteomics markers. METHODS: In our previous study we used DIA proteomics to screen for proteins that were significant in 31 PCOS patients compared to women of normal reproductive age. In this study, we used logistic regression among these protein markers to screen out variables with diagnostic value and constructed logistic regression models. RESULTS: We constructed a logistic model using these protein markers, where HIST1H4A (OR=1.037) was an independent risk factor for polycystic ovary syndrome and TREML1 (OR=0.976) were protective factors for the disease. The logistic regression model equation is: Logit (PCOS) =0.036*[HIST1H4A]-0.024*[TREML1]-16.368. The ROC curve analyzing the diagnostic value of the model has an AUC value of 0.977 and a Youden index of0.903, which gives a cutoff value of 0.518 at this point. The model has a sensitivity of 93.5% and a specificity of 96.8%. Calibration curves show fair consistency of the model. DISCUSSION: Our study is the first to use proteomic results with clinical biochemical data to construct a logistic regression model, and the model is consistent. However, our study still needs a more complete sample to confirm our findings. Frontiers Media S.A. 2023-10-03 /pmc/articles/PMC10579946/ /pubmed/37854181 http://dx.doi.org/10.3389/fendo.2023.1227252 Text en Copyright © 2023 Tong, Wu, Zhuang, Wang and Yu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Tong, Cheng
Wu, Yue
Zhuang, Zhenchao
Wang, Zhejiong
Yu, Ying
Combining proteomic markers to construct a logistic regression model for polycystic ovary syndrome
title Combining proteomic markers to construct a logistic regression model for polycystic ovary syndrome
title_full Combining proteomic markers to construct a logistic regression model for polycystic ovary syndrome
title_fullStr Combining proteomic markers to construct a logistic regression model for polycystic ovary syndrome
title_full_unstemmed Combining proteomic markers to construct a logistic regression model for polycystic ovary syndrome
title_short Combining proteomic markers to construct a logistic regression model for polycystic ovary syndrome
title_sort combining proteomic markers to construct a logistic regression model for polycystic ovary syndrome
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579946/
https://www.ncbi.nlm.nih.gov/pubmed/37854181
http://dx.doi.org/10.3389/fendo.2023.1227252
work_keys_str_mv AT tongcheng combiningproteomicmarkerstoconstructalogisticregressionmodelforpolycysticovarysyndrome
AT wuyue combiningproteomicmarkerstoconstructalogisticregressionmodelforpolycysticovarysyndrome
AT zhuangzhenchao combiningproteomicmarkerstoconstructalogisticregressionmodelforpolycysticovarysyndrome
AT wangzhejiong combiningproteomicmarkerstoconstructalogisticregressionmodelforpolycysticovarysyndrome
AT yuying combiningproteomicmarkerstoconstructalogisticregressionmodelforpolycysticovarysyndrome